Table 3.

Tumor response to therapy

Response according to irRC	Patients, N = 50(%)	Melanoma diagnosi n (%)		Performance status n (%)		M stage n (%)				LDH level
		cutaneous	uveal	ECOG 0–1	ECOG ≥ 2	M1a	M1b	M1c	M1c-brain	< ULN	≥≥ ULN
irCR	1 (2%)	1 (2%)	0	1 (2%)	0	1 (2%)	0	0	0	1 (2%)	0
irPR	5 (10%)	5 (10%)	0	5 (10%)	0	0	2 (4%)	3 (6%)	1 (2%)	3 (6%)	2 (4%)
irSD	9 (18%)	7 (14%)	2 (4%)	9 (18%)	0	3 (6%)	1 (2%)	5 (12%)	0	6 (12%)	3 (6%)
irPD	35 (70%)	28 (56%)	7 (14%)	27 (54%)	8 (16%)	4 (8%)	3 (6%)	27 (54%)	8 (16%)	13 (26%)	22 (44%)

irCR – immune-related complete response; irPR – immune-related partial response; irSD – immune-related stable disease; irPD – immune-related progressive disease; LDH – lactate dehydrogenase; ULN – upper limit of normal